EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis

Sudha S Shankar, Samuel J Daniels, Darren Robertson, Janeli Sarv, José Sánchez, Debra Carter, Lutz Jermutus, Benjamin Challis, Arun J Sanyal

Clinical Gastroenterology and Hepatology · 2024

DOI: 10.1016/j.cgh.2024.04.017 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2024. Verfasst von Sudha S Shankar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Early Clinical Development, Early Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland; Translational S…. Hauptthemen laut MEDLINE: Incretins. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Gilead Sciences, Novartis, AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Cotadutide, a peptide co-agonist at the glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptors, has demonstrated robust improvements in body weight, glycemia, and hepatic fat fraction (HFF) in patients living with obesity and type 2 diabetes mellitus. METHODS: In PROXYMO, a 19-week randomized double-blind placebo-controlled trial, the safety and efficacy of cotadutide (600 μg, 300 μg) or placebo were evaluated in 74 participants with biopsy-proven noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis. Analyses were performed using intent-to-treat and modified intent-to-treat population data. RESULTS: Dose- and time-dependent improvements in HFF, alanine aminotransferase (ALT), and aspartate aminotransferase (AST), markers of liver health, and metabolic parameters were observed with significant improvements after 19 weeks with 600 μg ([least squares] mean difference vs placebo, [95% confidence interval] for absolute HFF: -5.0% [-8.5 to -1.5]; ALT: -23.5 U/L [-47.1 to -1.8]; AST: -16.8 U/L [-33.0 to -0.8]). Incidences of any grade treatment-emergent adverse events (TEAEs) were 91.7%, 76.9%, and 37.5% with cotadutide 600 μg, 300 μg, and placebo, respectively. The majority were gastrointestinal, mild to moderate in severity, and generally consistent with other incretins at this stage of development. TEAEs leading to treatment discontinuation were 16.7%, 7.7%, and 4.2% with cotadutide 600 μg, 300 μg, and placebo, respectively. CONCLUSIONS: PROXYMO provides preliminary evidence for the safety and efficacy of GLP-1/GCG receptor co-agonism in biopsy-proven noncirrhotic MASH with fibrosis, supporting further evaluation of this mechanism in MASH. CLINICAL TRIAL REGISTRATION NUMBER: NCT04019561.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IncretinsHumansFemaleMaleMiddle AgedDouble-Blind MethodAdultTreatment OutcomePlacebosAgedBiopsyLiver CirrhosisDrug-Related Side Effects and Adverse ReactionsFatty LiverYoung Adult

Stichwörter der Autor:innen

CotadutideHepatic FatLiver ToxicityMetabolic Dysfunction-Associated Steatohepatitis

Substanzen

PlacebosIncretins

Autor:innen und Institutionen

  • Early Clinical Development, Early Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland; Translational Science and Experimental Medicine, Research and Early Cardiovascular, R…
  • Early Clinical Development, Early Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland.
  • Early Biometrics & Statistical Innovation, Data Science & Artificial Intelligence, R&D, AstraZeneca, Gothenburg, Sweden.
  • Global Patient Safety, Astra Zeneca, Gaithersburg, Maryland.
  • Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
  • Translational Science and Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.

Förderung

  • Gilead Sciences
  • Novartis
  • AstraZeneca

Zitieren

APA

Shankar, S. S., Daniels, S. J., Robertson, D., Sarv, J., Sánchez, J., Carter, D., Jermutus, L., Challis, B., & Sanyal, A. J. (2024). Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2024.04.017

Vancouver

Shankar SS, Daniels SJ, Robertson D, Sarv J, Sánchez J, Carter D, et al. Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis. Clinical Gastroenterology and Hepatology. 2024. doi:10.1016/j.cgh.2024.04.017

BibTeX
@article{Shankar2024,
  author = {Shankar, Sudha S and Daniels, Samuel J and Robertson, Darren and Sarv, Janeli and Sánchez, José and Carter, Debra and Jermutus, Lutz and Challis, Benjamin and Sanyal, Arun J},
  title = {Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2024},
  doi = {10.1016/j.cgh.2024.04.017}
}
Kostenlos starten →